Semaglutide Pills and Injections for Type 2 Diabetes in Argentina, Followed Over 1 Year
Observes how semaglutide works in adults with type 2 diabetes in Argentina.
Plain-language title generated from the registry record
Registry title: Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin
Key facts
- Where
- Buenos Aires, ArgentinaSee the 2 sites
Where in Argentina
- Hospital General de Agudos Dr Enrique TornúBuenos Aires, ArgentinaTaking people
- Hospital Italiano de Buenos AiresBuenos Aires, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Italiano de Buenos Aires
- Trial code
- NCT07621419
- Record updated
- 2 June 2026
- Original description
The goal of this prospective, multicenter, observational study is to evaluate the real-world effectiveness and safety of oral and subcutaneous semaglutide in adults with type 2 diabetes mellitus in Argentina. The main objective is to assess changes in glycated hemoglobin (HbA1c) from baseline to 3, 6, and 12 months after treatment initiation. Secondary objectives include evaluating changes in body weight, waist circumference, hand-grip strength, treatment satisfaction, medication adherence, treatment route switching, treatment discontinuation, and adverse events.Read full original descriptionShow less
New Formulation of Semaglutide in the Treatment of Type 2 Diabetes in Argentina: a Prospective, Multicenter, Real-world Study
The goal of this prospective, multicenter, observational study is to evaluate the real-world effectiveness and safety of oral and subcutaneous semaglutide in adults with type 2 diabetes mellitus in Argentina. The main objective is to assess changes in glycated hemoglobin (HbA1c) from baseline to 3, 6, and 12 months after treatment initiation. Secondary objectives include evaluating changes in body weight, waist circumference, hand-grip strength, treatment satisfaction, medication adherence, treatment route switching, treatment discontinuation, and adverse events.
Participants will receive semaglutide as prescribed by their treating physician as part of routine clinical care. Follow-up assessments will be performed at 3, 6, and 12 months to collect clinical, laboratory, safety, treatment satisfaction, and adherence data. Treatment satisfaction will be assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and adherence will be assessed using the Simplified Medication Adherence Questionnaire (SMAQ).
Inclusion: Age ≥ 18 years; Clinical diagnosis of type 2 diabetes mellitus; Baseline glycated hemoglobin (HbA1c) >7% and ≤12%; Initiating treatment with semaglutide (oral or subcutaneous) prescribed by the treating physician according to clinical judgment.
Exclusion: History of severe hypersensitivity or adverse reactions to glucagon-like peptide-1 (GLP-1) receptor agonists; Contraindications to semaglutide as listed in the product label (e.g., severe gastrointestinal disease, certain endocrine tumors); Any other serious medical condition that, in the investigator's opinion, may interfere with study participation or data interpretation; Pregnancy or lactation at the time of enrollment.